U.S., Nov. 22 -- ClinicalTrials.gov registry received information related to the study (NCT07243015) titled 'Detection of Minimal Residual Disease Using Exosomal miRNA Distant Metastasis Markers' on Nov. 17.
Brief Summary: Gastric cancer (GC) is a leading cause of cancer-related death worldwide. Even in patients undergoing curative surgery for non-metastatic disease, postoperative recurrence frequently occurs due to undetected minimal residual disease (MRD). This study aims to establish a highly sensitive and specific liquid biopsy assay using exosomal microRNAs (exo-miRNAs) to detect MRD and predict distant metastasis before clinical recurrence.
Study Start Date: Jan. 15
Study Type: OBSERVATIONAL
Condition:
Gastric Cancer
Interventio...